☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
pemphigus vulgaris
Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study for Pemphigus Vulgaris
October 14, 2019
Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphig...
June 13, 2019
Roche's MabThera (rituximab) Receives EU's Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV)
March 15, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.